Stayble Therapeutics is a clinical-stage company developing a truly innovative, non-surgical product (STA-363) to permanently alleviate discogenic chronic low back pain (cLBP). Discogenic cLBP is globally one of the costliest and most disabling medical conditions affecting more than 50 million people on a daily basis. STA-363 is a disease-modifying, permanent, single injection treatment. The product vision of STA-363 is to become the new standard of care for patients with discogenic cLBP.
Startup stories about Stayble Therapeutics